Comparative study of erythromycin, amoxicillin and ampicillin antimicrobial activity against human respiratory tract pathogens

• Published in: Scandinavian journal of infectious diseases. Supplementum no. 20; p. 1
• Main Authors: Liss, R H, Norman, J C, Goldmann, D A
• Format: Journal Article
• Language: English
• Published: England 1979
• Subjects: Amoxicillin - pharmacology; Ampicillin - pharmacology; Bacteria - drug effects; Bacteria - ultrastructure; Cell Wall - ultrastructure; Erythromycin - pharmacology; Haemophilus influenzae - drug effects; Humans; Microbial Sensitivity Tests; Microscopy, Electron; Respiratory System - microbiology; Staphylococcus aureus - drug effects; Streptococcus pneumoniae - drug effects; Streptococcus pyogenes - drug effects
• ISSN: 0300-8878

An in vitro test system was used to compare the antimicrobial activity of erythromycin, amoxicillin and ampicillin against respiratory tract pathogens isolated from man. The minimum inhibitory concentrations (MICs) of fresh clinical isolates of Streptoccus pyogenes, Streptocuccus pneumoniae, Staphylococcus aureus and Haemophilus influenzae to the macrolide and penicillins ranged between 0.01 and 0.9 microgram/ml. The microbes were exposed to each antibiotic for approximately 3 h at 1x,2x and 5x the relevant MIC. Irreversible surface defects and intracellular lesions were resolved by scanning and transmission electron microscopy in all antibiotic-treated bacterial species, irrespective of the antimicrobial used. In each case, inhibition of growth was recorded by turbometric assay; no significant difference was observed among the declining slopes of post-dosing growth curves for either erythromycin-, amoxicillin- or ampicillin-treated pathogens. The experimental observations show that the onset of antimicrobial activity and the bactericidal effectiveness of equipotent concentrations of erythromycin, amoxicillin and ampicillin were comparable in this study. The results complement previous clinical, bacteriologic and ultrastructure studies in vivo and demonstrate the contribution of the combined in vivo/in vitro study design for better understanding of antimicrobial activity in human respiratory tract infections.